NO20082165L - Bifenylderivater som modulatorer av spenningsstyrte ionekanaler - Google Patents

Bifenylderivater som modulatorer av spenningsstyrte ionekanaler

Info

Publication number
NO20082165L
NO20082165L NO20082165A NO20082165A NO20082165L NO 20082165 L NO20082165 L NO 20082165L NO 20082165 A NO20082165 A NO 20082165A NO 20082165 A NO20082165 A NO 20082165A NO 20082165 L NO20082165 L NO 20082165L
Authority
NO
Norway
Prior art keywords
modulators
voltage controlled
biphenyl derivatives
ion channels
controlled ion
Prior art date
Application number
NO20082165A
Other languages
English (en)
Norwegian (no)
Inventor
Esther Martinborough
Nicole Zimmermann
Aarti Sameer Kawatkar
Timothy Neubert
Andreas Termin
Danielle Lehsten
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20082165L publication Critical patent/NO20082165L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
NO20082165A 2005-10-12 2008-05-13 Bifenylderivater som modulatorer av spenningsstyrte ionekanaler NO20082165L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72568605P 2005-10-12 2005-10-12
PCT/US2006/040156 WO2007047474A2 (fr) 2005-10-12 2006-10-12 Derives de biphenyle utilises comme modulateurs des canaux ioniques sensibles au voltage

Publications (1)

Publication Number Publication Date
NO20082165L true NO20082165L (no) 2008-07-09

Family

ID=37836784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082165A NO20082165L (no) 2005-10-12 2008-05-13 Bifenylderivater som modulatorer av spenningsstyrte ionekanaler

Country Status (15)

Country Link
US (2) US7683083B2 (fr)
EP (1) EP1934191B1 (fr)
JP (1) JP2009511599A (fr)
KR (1) KR20080059292A (fr)
CN (1) CN101365690A (fr)
AT (1) ATE551333T1 (fr)
AU (1) AU2006304283B2 (fr)
CA (1) CA2624831A1 (fr)
ES (1) ES2383090T3 (fr)
IL (1) IL190632A0 (fr)
NO (1) NO20082165L (fr)
NZ (1) NZ567570A (fr)
RU (1) RU2008118350A (fr)
WO (1) WO2007047474A2 (fr)
ZA (1) ZA200803704B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
MX2007014180A (es) * 2005-05-10 2008-01-14 Vertex Pharma Derivados biciclicos como moduladores de canales de iones.
CA2608599A1 (fr) * 2005-05-16 2006-11-23 Vertex Pharmaceuticals Incorporated Derives bicycliques en tant que modulateurs de canaux ioniques
MX2008003337A (es) 2005-09-09 2008-09-26 Vertex Pharma Derivados biciclicos como modulares de canales ionicos regulados por voltaje.
EP1934191B1 (fr) * 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Derives de biphenyle utilises comme modulateurs des canaux ioniques sensibles au voltage
CN101331115A (zh) * 2005-10-21 2008-12-24 沃泰克斯药物股份有限公司 调控离子通道的衍生物
EP2316829A1 (fr) * 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
MX2009012678A (es) 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
WO2009064752A2 (fr) * 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques utilisés comme modulateurs des canaux ioniques
US7994166B2 (en) * 2007-11-13 2011-08-09 Vertex Pharmaceuticals Incorporated Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain
WO2009133641A1 (fr) * 2008-04-30 2009-11-05 シャープ株式会社 Dispositif d'éclairage et dispositif d'affichage
WO2010002956A2 (fr) * 2008-07-01 2010-01-07 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
GB201209015D0 (en) * 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
EP2935257B1 (fr) * 2012-12-20 2018-02-07 Purdue Pharma LP Sulfonamides cycliques en tant que bloquants des canaux sodiques
RS56015B1 (sr) 2013-01-31 2017-09-29 Vertex Pharma Piridon amidi kao modulatori natrijumovih kanala
WO2019077106A1 (fr) * 2017-10-19 2019-04-25 Esteve Pharmaceuticals, S.A. Nouveaux composés alkoxyamino permettant de traiter la douleur et des états pathologiques associés à la douleur
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
CA3105657A1 (fr) 2018-07-09 2020-01-16 Lieber Institute, Inc. Composes de pyridine carboxamide pour inhiber nav1.8
WO2020163236A1 (fr) * 2019-02-04 2020-08-13 The General Hospital Corporation Traitement du syndrome du qt long congénital
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2002039987A2 (fr) 2000-11-14 2002-05-23 Neurosearch A/S Mise en oeuvre de bloquants des canaux anioniques des parasites de la malaria pour traiter cette maladie
MXPA04004837A (es) * 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL160630A0 (en) * 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1673357A2 (fr) * 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants
EP1696915A1 (fr) 2003-12-19 2006-09-06 Pfizer, Inc. Derives de benzenesulfonylamino-pyridin-2yl et composes apparentes en tant qu'inhibiteurs de la 11-beta-hydeoxysteroide deshydrogenase type 1 (11-beta-hsd-1) pour le traitement du diabete et de l'obesite
WO2006089871A2 (fr) * 2005-02-23 2006-08-31 Neurosearch A/S Derives de diphenyluree utiles en tant qu'agents d'ouverture de canal erg pour le traitement d'arythmies cardiaques
EP1934191B1 (fr) * 2005-10-12 2012-03-28 Vertex Pharmaceuticals, Inc. Derives de biphenyle utilises comme modulateurs des canaux ioniques sensibles au voltage

Also Published As

Publication number Publication date
CA2624831A1 (fr) 2007-04-26
WO2007047474A2 (fr) 2007-04-26
AU2006304283B2 (en) 2012-01-19
EP1934191A2 (fr) 2008-06-25
ZA200803704B (en) 2009-09-30
KR20080059292A (ko) 2008-06-26
ATE551333T1 (de) 2012-04-15
US20080113990A1 (en) 2008-05-15
AU2006304283A1 (en) 2007-04-26
US20100130548A1 (en) 2010-05-27
WO2007047474A3 (fr) 2007-07-05
ES2383090T3 (es) 2012-06-18
CN101365690A (zh) 2009-02-11
JP2009511599A (ja) 2009-03-19
NZ567570A (en) 2011-02-25
US7683083B2 (en) 2010-03-23
EP1934191B1 (fr) 2012-03-28
RU2008118350A (ru) 2009-11-20
IL190632A0 (en) 2008-11-03
US8236833B2 (en) 2012-08-07

Similar Documents

Publication Publication Date Title
NO20082165L (no) Bifenylderivater som modulatorer av spenningsstyrte ionekanaler
NO20081725L (no) Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
WO2008112715A3 (fr) Nouveaux agents modulateurs des canaux d'ions calcium
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
WO2008147797A3 (fr) Modulateurs de canal ionique et leurs procédés d'utilisation
WO2009035818A8 (fr) Composés modulant le calcium intracellulaire
HN2009001112A (es) Inhibidores de la actividad de la akt
WO2007145704A3 (fr) Thérapie de combinaison de gemcitabine
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
CR9869A (es) Compuestos activos en ppar
WO2010025295A3 (fr) Composés modulant le calcium intracellulaire
NO20060202L (no) Pyrrolodihydroisokinoliner som PDE-10-inhibitorer
WO2010036630A3 (fr) Composés modulant sélectivement le récepteur cb2
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
ECSP088369A (es) Novedosos derivados de 1-aza-bicicloalquilo para el tratamiento de trastornos psicóticos y neurodegenerativos
ATE538084T1 (de) Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application